Ribi, Karin, Luo, Weixiu, Ruhstaller, Thomas, Abdi, Ehtesham, Biganzoli, Laura, Müller, Bettina, Barbeaux, Annelore, Graas, Marie-Pascale, Rabaglio, Manuela, Francis, Prudence A., Foukakis, Theodoros, Pagani, Olivia, Colleoni, Marco, Graiff, Claudio, Vorobiof, Daniel, Maibach, Rudolf, Di Leo, Angelo, Gelber, Richard D., Goldhirsch, Aron, Coates, Alan S., Regan, Meredith M., Bernhard, Jürg, Karlsson, Per, Chirgwin, Jacquie, Aebi, Stefan, Jerusalem, Guy, Neven, Patrick, Di Lauro, Vincenzo, Gomez, Henry L.. Nature Publishing Group; 2019. Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.

Goldhirsch, A., Winer, E. P., Bonnefoi, Hervé, Bretel-Morales, Denisse, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Colleoni, Marco, Costa, Alberto, Curigliano, Giuseppe, Davidson, Nancy E., Leo, Angelo Di, Coates, A. S., Ejlertsen, Bent, Forbes, John F., Gelber, Richard D., Gnat, Michael, Goldhirsch, Aron, Goodwin, Pamela, Goss, Paul E., Harris, Jay R., Hayes, Daniel F., Hudis, Clifford A., Gelber, R. D., Ingle, James N., Jassem, Jacek, Jiang, Zefei, Karlsson, Per, Loibl, Sibylle, Morrow, Monica, Namer, Moise, Osborne, C. Kent, Partridge , Ann H., Penault-Llorca, Fréderiqué, Piccart-Gebhart, M., Perou, Charles M., Piccart-Gebhart, Martine, Pritchard, Kathleen I., Rutgers, Emiel J. T., Sedlmayer, Felix, Semiglazov, Vladimir, Shao, Zhi-Ming, Smith, Ian, Thürlimann, Beat, Toi, Masakazu, , Tutt, Andrew, Untch, Michael, Viale, Giuseppe, Watanabe, Toru, Wilcken, Nicholas, Winer, Eric P., Wood, William C., Senn, H. - J., Albain, Kathy S., André, Fabrice, Bergh, Jonas. Oxford University Press; 2013. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013.

Phillips, Kelly-Anne, Regan, Meredith, Abdi, Ehtesham, Domchek, Susan, Feng, Yang, Price, Karen, Coates, Alan, Gelber, Richard, Maruff, Paul, Boyle, Frances, Forbes, John F., Ahles, Tim, Ribi, Karin, Fleming, Gini, Bernhard, Jürg, Francis, Prudence A., Puglisi, Fabio, Bellet, Meritxell, Spazzapan, Simon, Karlsson, Per, Budman, Daniel, Zaman, Khalil. Nature Publishing; 2016. Adjuvant ovarian function suppression and cognitive function in women with breast cancer.

Ribi, Karin, Luo, Weixiu, Parmar, Vani, Tondini, Carlo, Kerbrat, Pierre, Perelló, Antonia, Neven, Patrick, Torres, Roberto, Lombardi, Davide, Puglisi, Fabio, Karlsson, Per, Ruhstaller, Thomas, Bernhard, Jürg, Colleoni, Marco, Coates, Alan S., Goldhirsch, Aron, Price, Karen N., Gelber, Richard D., Regan, Merideth M., Fleming, Gini F., Francis, Prudence A., Burstein, Harold J., Ciruelos, Eva, Bellet, Meritxell, Pavesi, Lorenzo, Lluch, Ana, Visini, Marilena. American Society of Clinical Oncology; 2016. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial.

Colleoni, Marco, Sun, Zhuoxin, Goldhirsch, Aron, Price, Karen N., Karlsson, Per, Forbes, John F., Thürlimann, Beat, Gianni, Lorenzo, Castiglione, Monica, Gelber, Richard D., Coates, Alan S.. American Society of Clinical Oncology; 2016. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V.